Peptidomimetic therapeutics: scientific approaches and opportunities.

Peptidomimetic therapeutics: scientific approaches and opportunities.
复制标题

DOI:
10.1016/j.drudis.2016.11.003
复制
发表时间:
2017-03
影响因子:
7.4
通讯作者:
Gross ER
Gross ER
中科院分区:
医学2区
文献类型:
--
作者:
Qvit N;Rubin SJS;Urban TJ;Mochly-Rosen D;Gross ER

文献摘要

参考文献

被引文献

相似文献

天然内源性多肽具有理想的药用特性,但由于蛋白质水解速度快和膜通透性不足,往往限制了其应用。然而,编辑天然存在的肽序列以开发拟肽类似物创造了一类有前途的治疗方法,可以增强或抑制分子相互作用。在这里,我们讨论了各种化学修饰,包括L到D异构化,环化和非天然氨基酸取代,以及设计策略,如附着在细胞穿透肽上,用于开发拟肽。我们还提供了批准的肽类药物的例子,并讨论了几种化合物在临床试验。
Natural endogenously occurring peptides exhibit desirable medicinal properties, but are often limited in application by rapid proteolysis and inadequate membrane permeability. However, editing naturally occurring peptide sequences to develop peptidomimetic analogs created a promising class of therapeutics that can augment or inhibit molecular interactions. Here, we discuss a variety of chemical modifications, including L to D isomerization, cyclization, and unnatural amino acid substitution, as well as design strategies, such as attachment to cell-penetrating peptides, which are used to develop peptidomimetics. We also provide examples of approved peptidomimetics and discuss several compounds in clinical trials.
DOI: 10.2147/idr.s99046
发表时间: 2016
影响因子: 3.9
作者:
Gonzalez-Ruiz A;Seaton RA;Hamed K
通讯作者: Hamed K
DOI: 10.1126/science.7973629
发表时间: 1994-11-04
期刊: SCIENCE
影响因子: 56.9
作者:
DAWSON, PE;MUIR, TW;KENT, SBH
通讯作者: KENT, SBH
DOI: 10.1161/01.hyp.37.2.342
发表时间: 2001-02-01
期刊: HYPERTENSION
影响因子: 8.3
作者:
Gavras, H;Brunner, HR
通讯作者: Brunner, HR
DOI: 10.1021/acs.molpharmaceut.5b00082
发表时间: 2015-06-01
影响因子: 4.9
作者:
Hallam, Trevor J.;Wold, Erik;Smider, Vaughn V.
通讯作者: Smider, Vaughn V.
DOI: 10.1073/pnas.1214518110
发表时间: 2013-02-19
影响因子: 11.1
作者:
Amiram, Miriam;Luginbuhl, Kelli M.;Chilkoti, Ashutosh
通讯作者: Chilkoti, Ashutosh